Fracture of the medial intercondylar eminence of the tibia in horses treated by arthroscopic fragment removal (21 horses)          下载免费PDF全文

L. M. Rubio‐Martínez  W. R. Redding  B. Bladon  H. Wilderjans  R. J. Payne  C. Tessier  O. Geffroy  R. Parker  C. Bell  F. A. Collingwood 《Equine veterinary journal》2018,50(1):60-64

  相似文献   

Bioavailability and tolerability of nebulised dexamethasone sodium phosphate in adult horses          下载免费PDF全文

A. D. Haspel  S. Giguère  K. A. Hart  L. J. Berghaus  J. L. Davis 《Equine veterinary journal》2018,50(1):85-90

  相似文献   

Pharmacokinetics of tiludronate in horses: A field population study          下载免费PDF全文

M. A. Popot  M. Jacobs  P. Garcia  B. Loup  J. Guyonnet  P. L. Toutain  L. Bailly‐Chouriberry  Y. Bonnaire 《Equine veterinary journal》2018,50(4):488-492

  相似文献   

Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals          下载免费PDF全文

K. D. MacDonald  K. A. Hart  J. L. Davis  L. J. Berghaus  S. Giguère 《Equine veterinary journal》2018,50(4):532-536

  相似文献   

Prevalence of headshaking within the equine population in the UK          下载免费PDF全文

S. E. Ross  J. K. Murray  V. L. H. Roberts 《Equine veterinary journal》2018,50(1):73-78

  相似文献   

Validation of masks for determination of V̇O2max in horses exercising at high intensity          下载免费PDF全文

R. H. Sides  R. Kirkpatrick  E. Renner  K. Gough  L. M. Katz  D. L. Evans  W. M. Bayly 《Equine veterinary journal》2018,50(1):91-97

  相似文献   

An improved vitrification protocol for equine immature oocytes,resulting in a first live foal          下载免费PDF全文

N. Ortiz‐Escribano  O. Bogado Pascottini  H. Woelders  L. Vandenberghe  C. De Schauwer  J. Govaere  E. Van den Abbeel  T. Vullers  C. Ververs  K. Roels  M. Van De Velde  A. Van Soom  K. Smits 《Equine veterinary journal》2018,50(3):391-397

  相似文献   

Elapid snake envenomation in horses: 52 cases (2006–2016)          下载免费PDF全文

N. J. Bamford  S. B. Sprinkle  L. A. Cudmore  A. M. Cullimore  A. W. van Eps  E. J. M. M. Verdegaal  B. S. Tennent‐Brown 《Equine veterinary journal》2018,50(2):196-201

  相似文献   

Effects of age and diet on glucose and insulin dynamics in the horse          下载免费PDF全文

J. L. Rapson  H. C. Schott II  B. D. Nielsen  L. J. McCutcheon  P. A. Harris  R. J. Geor 《Equine veterinary journal》2018,50(5):690-696

  相似文献   

Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin          下载免费PDF全文

C.J. Henry  B.K. Flesner  S.A. Bechtel  J.N. Bryan  D.J. Tate  K.A. Selting  J.C. Lattimer  M.E. Bryan  L. Grubb  F. Hausheer 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2018,32(1):370-376

Background

Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diuresis volume in clinical trials in humans.

Hypothesis/Objectives

We hypothesized that Tavocept would decrease diuresis volume and time and facilitate safe administration of a cisplatin/piroxicam protocol to dogs with bladder cancer. Secondary objectives were to compare response rate and survival times to an historical comparator group treated without Tavocept.

Animals

Fourteen client‐owned dogs were prospectively enrolled.

Methods

Tumor volume was measured by computed tomography at days 0, 42, and 84. Dogs received combination Tavocept/cisplatin with a shortened diuresis protocol. A total of 4 doses was planned, with concurrent administration of piroxicam. Serial biochemical analyses were evaluated for azotemia.

Results

A 90‐minute infusion/diuresis time was used for all dogs. Three dogs (21%) had concurrent increases in serum creatinine (>2.0 mg/dL) and BUN (>42 mg/dL) concentrations; 2 of these dogs were isosthenuric. This frequency of nephrotoxicity is significantly less (P = 0.0406) than that of an historical control group treated without Tavocept. Overall response rate was 27%. Median survival time was comparable to historical controls (253 vs. 246 days).

Conclusions and Clinical Importance

Tavocept decreased the required diuresis time with cisplatin from > 6 hours to 90 minutes, while also decreasing occurrence of azotemia. Survival time was comparable, but the response rate was inferior to an historical comparator group. Further evaluation in other tumors susceptible to platinum agents is warranted.  相似文献